Enhancing conjugation efficiency by engineering thiol groups at targeted sites.
Creative Biolabs provides high-precision ADC conjugation services that bridge the gap between antibody development and advanced biochemical applications. We provide end-to-end support, including specialized linker-payload design, optimized conjugation protocols, and rigorous analytical verification. Our clients can expect to gain access to highly homogeneous conjugates with verified drug-to-antibody ratios (DAR), reduced aggregation, and enhanced structural stability. By utilizing our platform, researchers obtain high-quality molecular entities that provide clear, reproducible data for complex biochemical assays and early-stage discovery pipelines.
For a complete ADC, the antibody is the key component to determine the target specificity with the capability to deliver the cytotoxic payload. Via a wide range of conjugation chemistry, the payload drugs can be attached to various sites on an antibody. Antibody conjugation can be generated by: natural amino acids; interchain disulfides; engineered cysteines; non-natural amino acids; carbohydrate moiety; N-terminus of heavy and light chain; engineered tags; strong protein-protein interaction such as Fc-binding domains which can be used to form non-covalent antibody conjugates; nucleotide binding site which is a valuable antibody modification site for photoaffinity labeling; antibodies with catalytic activity can be developed to form bioconjugates.
We offer various solutions for multiple potential conjugation sites of endogenous amino acids. In addition, we provide special moieties conjugation engineering services to achieve more precise site-directed conjugations and a narrower distribution of DAR.
Fig.1 Structure and Mechanism of Action of ADC. 1
ADC Conjugation Methods
Creative Biolabs offers near-physiological conditions to perform ADC conjugation reactions to ensure antibody bioactivity. With senior scientists and technicians, we established several platforms, including endogenous amino acids and other sites, especially lysine conjugation, cysteine conjugation, and tyrosine conjugation.
| Method | Advantages | Disadvantages | Applications |
|---|---|---|---|
| Lysine Conjugation | High payload loading | Heterogeneous DAR | Broad applicability |
| Cysteine Conjugation | Stable and site-specific | Requires reduction | Homogeneous ADCs |
| Tyrosine Conjugation | Minimal off-target modifications | Limited tyrosine residues | Specialized designs |
| Enzymatic Conjugation | Exceptional precision | Enzyme-substrate dependency | Homogeneous, advanced ADCs |
ADC Design and Engineering Services
Creative Biolabs offers advanced methodologies for antibody design and engineering, enabling the introduction of precise and chemically versatile conjugation sites to optimize antibody-drug conjugates (ADCs). To achieve a consistent and narrower drug-to-antibody ratio (DAR), our solutions include:
Enhancing conjugation efficiency by engineering thiol groups at targeted sites.
Genetic incorporation of residues like p-Acetyl Phenylalanine for site-specific conjugation.
Utilizing enzymes such as transglutaminases and formylglycine-generating enzymes for precise site modifications.
Creating specific binding cavities to enable controlled payload attachment.
Facilitating modular and seamless payload conjugation through intein-based engineering.
Modifying glycan moieties for site-directed drug attachment.
We combine deep biological insights with chemical precision, providing a unique hybrid approach that standard providers often lack during development.
Our team analyzes how payload attachment influences the antibody's isoelectric point (pI) and critical biochemical characteristics for better performance.
Supported by Published Data, our site-specific conjugates demonstrate a multi-fold increase in molecular stability over traditional stochastic conjugation methods.
We utilize a validated platform to ensure every conjugate meets rigorous standards for homogeneity, stability, and predictable research performance.
Discover how we can help - Get a quote today.
DAR (drug-to-antibody ratio) determines the number of payload molecules attached to each antibody. An optimized DAR ensures balanced efficacy and safety, reducing toxicity and maximizing therapeutic windows.
Our advanced methodologies, including enzymatic conjugations and engineered antibodies, precisely target desired conjugation sites, minimizing off-target modifications.
We provide custom synthesis of high-purity payloads and innovative linkers, including cleavable and non-cleavable options for specialized discovery and development applications.
Learn More →We offer comprehensive biochemical validation, including drug-load distribution, purity analysis, and thermal stability assessments, to ensure consistent molecular performance across discovery projects.
Learn More →An appropriate conjugation design and chemistry are critically important for the success of an ADC product. With advanced antibody design platforms and solutions, Creative Biolabs is dedicated to being your best companion in producing customized ADCs tailored to best fit your project. We are committed to maximizing your success. For more information or a detailed quote, please feel free to contact us.
Reference